Select Publications

Bachelot T et al. TAMRAD: A GINECO randomized Phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). San Antonio Breast Cancer Symposium 2010;Abstract S1-6.

Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9. Abstract

Baselga J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19. Abstract

Cortés J et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30(14):1594-600. Abstract

Cortés J et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 2011;377(9769):914-23. Abstract

Gianni L et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). San Antonio Breast Cancer Symposium 2011;Abstract S4-8.

Gianni L et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(7):1131-7. Abstract

Gradishar WJ. HER2 therapy — An abundance of riches. N Engl J Med 2012;366(2):176-8. Abstract

Hurvitz S et al. Trastuzumab emtansine (T-DM1) versus trastuzumab plus docetaxel (H + T) in previously untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label, phase II study (TDM4450g/BO21976). Proc EMCC 2011;Abstract 5001.

Isakoff SJ et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. Proc ASCO 2010;Abstract 1019.

Lehmann BD et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121(7):2750-67. Abstract

Martinez de Dueñas E et al. Prospective evaluation of the conversion rate of HER2, ER and PR between primary tumors and corresponding metastases. CONVERTHER/GEICAM 2009-03 study. San Antonio Breast Cancer Symposium 2011;Abstract P2-12-17.

Mehta RS et al. A Phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. San Antonio Breast Cancer Symposium 2011;Abstract S1-1.

Miller KD et al. PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA 1/2 mutations: Hoosier Oncology Group BRE09-146. San Antonio Breast Cancer Symposium 2011;Abstract OT3-01-05.

Mirtsching B et al. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer 2011;11(2):121-8. Abstract

Montero AJ et al. Nab-paclitaxel in the treatment of metastatic breast cancer: A comprehensive review. Expert Rev Clin Pharmacol 2011;4(3):329-34. Abstract

Montero AJ, Vogel C. Fighting fire with fire: Rekindling the bevacizumab debate. N Engl J Med 2012;366(4):374-5. Abstract

Paterson AHG et al. NSABP protocol B-34: A clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy — Final analysis. San Antonio Breast Cancer Symposium 2011;Abstract S2-3.

Solin LJ. Selecting individualized treatment for patients with ductal carcinoma in situ of the breast: The search continues. J Clin Oncol 2012;30(6):577-9. Abstract

Yardley DA et al. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin Breast Cancer 2011;11(5):297-305. Abstract